Comparative effectiveness of rivaroxaban versus a vitamin K antagonist in patients with renal impairment treated for non-valvular atrial fibrillation in Germany — A retrospective cohort study☆
Under a Creative Commons license
open access
Abbreviations
AF
atrial fibrillation
CHADS2
Congestive heart failure, Hypertension, Age ≥ 75 years, Diabetes mellitus, Stroke or transient ischaemic attack (2 points)
CHA2DS2-VASc
Congestive heart failure, Hypertension, Age ≥ 75 years (2 points), Diabetes mellitus, Stroke or transient ischaemic attack (2 points), Vascular disease, Age 65–74, Sex category (female)
CI
confidence interval
DOAC
direct oral anticoagulant
eDDD
empirical defined daily dose
HAS-BLED
Hypertension, Abnormal renal/liver function, Stroke, Bleeding history or predisposition, Labile international normalised ratio, Elderly, Drugs/alcohol concomitantly
HR
hazard ratio
ICD-10
International Classification of Diseases Tenth Revision
ICH
intracranial haemorrhage
NVAF
non-valvular atrial fibrillation
od
once daily
VKA
vitamin K antagonist
pPDD
personalised prescribed daily dose
PY
patient-years
TIA
transient ischaemic attack
Keywords
Non-valvular atrial fibrillation
Phenprocoumon
RELOAD study
Renal impairment
Rivaroxaban
Cited by (0)
- ☆
Authors take responsibility for all aspects of the reliability and freedom from bias of the data presented and their discussed interpretation.
© 2019 The Authors. Published by Elsevier B.V.